{"protocolSection":{"identificationModule":{"nctId":"NCT05445895","orgStudyIdInfo":{"id":"RNX_002"},"organization":{"fullName":"SK Chemicals Co., Ltd.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke","officialTitle":"A Prospective, Randomized, Active-controlled, Double-blind, Parallel, Multi-center, Phase IV, Exploratory Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2022-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-12-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-06-30","studyFirstSubmitQcDate":"2022-06-30","studyFirstPostDateStruct":{"date":"2022-07-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-01-02","lastUpdatePostDateStruct":{"date":"2023-01-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"SK Chemicals Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke"},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":500,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Renexin CR 200/160mg","type":"EXPERIMENTAL","description":"Renexin CR 200/160mg will be added to Aspirin 100mg","interventionNames":["Drug: Renexin CR 200/160mg"]},{"label":"Clopidogrel 75mg","type":"ACTIVE_COMPARATOR","description":"Plavix 75mg will be added to Aspirin 100mg","interventionNames":["Drug: Plavix 75mg"]}],"interventions":[{"type":"DRUG","name":"Renexin CR 200/160mg","description":"Renexin CR 200/160mg will be added to Aspirin 100mg","armGroupLabels":["Renexin CR 200/160mg"]},{"type":"DRUG","name":"Plavix 75mg","description":"Plavix 75mg will be added to Aspirin 100mg","armGroupLabels":["Clopidogrel 75mg"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"- The sum of the rate of neurological deterioration during hospitalization after taking the IP and the rate of stroke up to 90 days","timeFrame":"up to 90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1) Patients identified as acute non-cardioembolic ischemic stroke on MRI within 72 hours of onset of symptoms of cerebral infarction.\n\nExclusion Criteria:\n\n1. Patients with active cancer; vascular malformation, abscess, or other major non-ischemic brain disease (e.g., multiple sclerosis).\n2. With a modified Rankin Score (mRS) of 3 or higher before onset.\n3. Underwent intravenous thrombolytic therapy (intravenous rtPA) or mechanical thrombectomy within 24 hours of the screening visit.\n4. History of hypersensitivity to IP or components\n5. Not suitable for aspirin administration at the discretion of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Sol-Ji Jung","role":"CONTACT","phone":"+82-2-2008-2590","email":"jungsolji@sk.com"}],"locations":[{"facility":"Asan Medical Center","status":"RECRUITING","city":"Seoul","country":"Korea, Republic of","contacts":[{"name":"Bum Joon Kim","role":"CONTACT"}],"geoPoint":{"lat":37.566,"lon":126.9784}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M1669","name":"Clopidogrel","asFound":"Proximal","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}